[1]刘洪庚,王 磊,朱 颜,等.他汀类药物在临床用药中的安全性[J].医学信息,2020,(11):46-48.[doi:10.3969/j.issn.1006-1959.2020.11.015]
 LIU Hong-geng,WANG Lei,ZHU Yan,et al.The Safety of Statins in Clinical Medicine[J].Medical Information,2020,(11):46-48.[doi:10.3969/j.issn.1006-1959.2020.11.015]
点击复制

他汀类药物在临床用药中的安全性()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2020年11期
页码:
46-48
栏目:
综述
出版日期:
2020-06-01

文章信息/Info

Title:
The Safety of Statins in Clinical Medicine
文章编号:
1006-1959(2020)11-0046-03
作者:
刘洪庚王 磊朱 颜
(天津医科大学中新生态城医院药剂科,天津 300467)
Author(s):
LIU Hong-gengWANG LeiZHU Yanet al
(Department of Pharmacy,Sino-Singapore Eco-city Hospital of Tianjin Medical University,Tianjin 300467,China)
关键词:
他汀类药物临床用药安全性
Keywords:
StatinsClinical medicationSafety
分类号:
R95
DOI:
10.3969/j.issn.1006-1959.2020.11.015
文献标志码:
A
摘要:
他汀类药物是临床心血管疾病治疗一线用药,属于临床一类广泛使用的口服降脂药物。目前,随着临床应用指南的不断更新,在治疗代谢性疾病、脑血管疾病、心血管疾病中均有应用。任何药物都存在潜在的毒性和不良反应,并且可能随着剂量增加治疗疗程的延长而增加。因此,研究他汀类药物在临床用药中的安全性具有重要的意义。本文对他汀类药物在临床用药中的安全性进行综述,以期为临床合理用药提供一定的参考。
Abstract:
Statins are the first-line drugs for the treatment of clinical cardiovascular diseases and belong to the clinically widely used oral lipid-lowering drugs. At present, with the continuous update of clinical application guidelines, it has been used in the treatment of metabolic diseases, cerebrovascular diseases and cardiovascular diseases. Any drug has potential toxicity and adverse reactions, and may increase as the dose increases and the course of treatment increases. Therefore, it is of great significance to study the safety of statins in clinical medicine. This article reviews the safety of statins in clinical medicine, in order to provide a certain reference for clinical rational medicine.

参考文献/References:

[1]吴小利.某院他汀类降血脂药物在临床中的应用和处方分析[J].临床合理用药,2017,10(10):80-81.[2]方任飞,李静湖,张杰,等.基于处方序列对称分析的他汀类药物肝脏安全性研究[J].中华流行病学杂志,2016,37(7):935-939.[3]楼勤.他汀类药物治疗高胆固醇血症合并脂肪肝的疗效和安全性研究[J].中国老年学杂志,2016,26(7):87.[4]李松霏,李文波,刘晓峰,等.他汀类药物对肝脏作用的再认识[J].中华医学杂志,2017,97(40):3194-3197[5]杨琼,张新宇,李小刚,等.他汀类药物在急性缺血性脑卒中的早期应用[J].中华老年心脑血管病杂志,2014,14(8):892-894.[6]刘志军,熊玉卿.药代动力学/药效学模型研究进展及其在他汀类药物临床治疗的应用[J].中国临床药理学杂志,2015,31(15):1552-1554.[7]Magni P,Macchi C,Morlotti B,et al.Risk identification and possible countermeasures for muscle adverse effects during statin therapy[J].Eur J Intern Med,2015,26(2):82-88. [8]方任飞,李静湖,张杰,等.基于处方序列对称分析的他汀类药物肝脏安全性研究[J].中华流行病学杂志,2016(37):935-939.[9]霍西茜,蒋立新.他汀类药物的国人临床研究与临床实践[J].中华内科杂志,2017,56(1):15-18.[10]Keyser CE,Koehler EM,Schouten JN,et al.Statin therapy is asso- ciated with a reduced risk of non-alcoholic fatty liver in overweight in individuals[J].Dig Liver Dis,2014,46(8):720-725. [11]陈爱荣.浅论他汀类药物所致不良反应的特点和预防措施[J].当代医药论丛,2017,15(16):130-131.[12]关欣亮,朱小玲,李艳芳,等.他汀类药物与新发糖尿病的风险[J].中华老年心脑血管病杂志,2012,14(12):1327-1329.[13]刘梅林,陈亚红.2015年《血脂异常老年人使用他汀类药物中国专家共识》解读[J].中国循环杂志,2015,30(Z2):75-76.[14]纪明慧.脑出血患者应用他汀类药物的安全性[J].实用医学杂志,2014,28(23):3863-3865.[15]Haynes R,Lewis D,Emberson J,etal.Effects of lowering LDL cholesterol on progression of kidney disease[J].J Am Soc Nephrol,2014,25(8):1825-1833. [16]赖诚民,陈勇.他汀类药物对老年冠心病患者动脉粥样硬化程度的影响[J].中国老年学杂志,2015,23(16):4507-4509.[17]胡鸿妍,王执兵.瑞舒伐他汀与阿托伐他汀治疗冠心病的效果对比观察[J].中国当代医药,2015,22(5):75-77.[18]Corrao G,Soranna D,Casula M,et al.High-potency statins increase the risk of acute kidney injury:Evidence from a large population-based study[J].Atherosclerosis,2014,234(1):224-229.[19]杨波,王来成.他汀类66例药品不良反应报告分析[J].安徽医药,2017,21(1):186-188.[20]国家药典委员会.中华人民共和国药典临床用药须知.化学药和生物制品卷(2015年版)[M].中国医药科技出版社,2015:303-310.[21]Mandal P,Chalmers JD,Graham C,et al.Atorvastatin as a stable treatment in bronchiectasis:a randomised controlled trial[J].Lancet Respir Med,2014,2(6):455-463. [22]王鹏.冠心病患者服用他汀类药物的疗效与安全性研究[D].山东大学,2016.[23]Abboud G,Kaplowitz N.Drug-Induced Liver Injury[J].Drug Saf,2007,30(4):277-294.[24]伍珩,韩雅玲,王效增,等.瑞舒伐他汀对急性冠脉综合征合并糖尿病轻中度肾功能不全患者介入诊治术后心肾功能的影响[J].解放军医学杂志,2014,39(7):546-552.[25]Fassett RG,Robertson IK,Ball MJ,et al.Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease[J].Clinical Nephrology,2013,81(2):75-85.[26]Wang KL,Liu CJ,Chao TF,et al.Risk of New-Onset Diabetes Mellitus Versus Reduction in Cardiovascular Events With Statin Therapy[J].American Journal of Cardiology,2014,113(4):631-636.[27]Dormuth CR,Filion KB,Paterson JM,et al.Higher potency statins and the risk of new diabetes:multicentre,observational study of administrative databases[J].BMJ,2014(348):g3244.

相似文献/References:

[1]韦 奇,高振轩,高 阳,等.他汀类药物联合抗血小板药物降低冠状动脉搭桥术后血管再狭窄的研究[J].医学信息,2019,(20):40.[doi:10.3969/j.issn.1006-1959.2019.20.012]
 WEI Qi,GAO Zhen-xuan,GAO Yang,et al.Study of Statins Combined with Antiplatelet Drugs to Reduce Vascular Restenosis after Coronary Artery Bypass Grafting[J].Medical Information,2019,(11):40.[doi:10.3969/j.issn.1006-1959.2019.20.012]

更新日期/Last Update: 1900-01-01